Alkaptonuria

References

• Garrod AE, Oxon MD. The incidence of alkaptonuria: a study in chemical individuality. 1902. Mol Med 1996; 2:274 - 82; PMID: 8784780
   PubMed Web of Science ®Google Scholar
• Phornphutkul C, Introne WJ, Perry MB, Bernardini I, Murphey MD, Fitzpatrick DL, Anderson PD, Huizing M, Anikster Y, Gerber LH, et al. Natural history of alkaptonuria. N Engl J Med 2002; 347:2111 - 21; http://dx.doi.org/10.1056/NEJMoa021736; PMID: 12501223
   PubMed Web of Science ®Google Scholar
• Suwannarat P, O’Brien K, Perry MB, Sebring N, Bernardini I, Kaiser-Kupfer MI, Rubin BI, Tsilou E, Gerber LH, Gahl WA. Use of nitisinone in patients with alkaptonuria. Metabolism 2005; 54:719 - 28; http://dx.doi.org/10.1016/j.metabol.2004.12.017; PMID: 15931605
   PubMed Web of Science ®Google Scholar
• Taylor AM, Wilson PJ, Ingrams DR, Helliwell TR, Gallagher JA, Ranganath LR. Calculi and intracellular ochronosis in the submandibular tissues from a patient with alkaptonuria. J Clin Pathol 2010; 63:186 - 8; http://dx.doi.org/10.1136/jcp.2009.071365; PMID: 20154043
   PubMed Web of Science ®Google Scholar
• Garcia SF, Egbert B, Swetter SM. Hereditary ochronosis: hyperpigmented skin overlying cartilaginous structures. Cutis 1999; 63:337 - 8; PMID: 10388955
   PubMed Web of Science ®Google Scholar
• Peker E, Yonden Z, Sogut S. From darkening urine to early diagnosis of alkaptonuria. Indian J Dermatol Venereol Leprol 2008; 74:700; http://dx.doi.org/10.4103/0378-6323.45142; PMID: 19180686
   PubMed Web of Science ®Google Scholar
• Keller JM, Macaulay W, Nercessian OA, Jaffe IA. New developments in ochronosis: review of the literature. Rheumatol Int 2005; 25:81 - 5; http://dx.doi.org/10.1007/s00296-004-0498-1; PMID: 15322814
   PubMed Web of Science ®Google Scholar
• Kraus VB. Rare osteoarthritis: Ochronosis, Kashin-Beck disease and Mseleni joint disease. In: Hochberg MC, Smolen SJ, Weinblatt ME, Weisman MH, ed. Rheumatology. 5th ed. Philadelphia (PA): Mosby; 2011 p1825-1837.
   Google Scholar
• Taylor AM, Boyde A, Wilson PJ, Jarvis JC, Davidson JS, Hunt JA, Ranganath LR, Gallagher JA. The role of calcified cartilage and subchondral bone in the initiation and progression of ochronotic arthropathy in alkaptonuria. Arthritis Rheum 2011; 63:3887 - 96; http://dx.doi.org/10.1002/art.30606; PMID: 22127706
   PubMed Web of Science ®Google Scholar
• Ranganath L, Taylor AM, Shenkin A, Fraser WD, Jarvis J, Gallagher JA, Sireau N. Identification of alkaptonuria in the general population: a United Kingdom experience describing the challenges, possible solutions and persistent barriers. J Inherit Metab Dis 2011; 34:723 - 30; http://dx.doi.org/10.1007/s10545-011-9282-z; PMID: 21311977
   PubMed Web of Science ®Google Scholar
• Develop AKUre. 950 AKU patients [Internet]. Cambridge (UK): The AKU Society and the DevelopAKUre Consortium: c2014 [cited 15 May 2013]. Available from: http://www.developakure.eu/950-aku-patients/
   Google Scholar
• Srsen S, Müller CR, Fregin A, Srsnova K. Alkaptonuria in Slovakia: thirty-two years of research on phenotype and genotype. Mol Genet Metab 2002; 75:353 - 9; http://dx.doi.org/10.1016/S1096-7192(02)00002-1; PMID: 12051967
   PubMed Web of Science ®Google Scholar
• Vilboux T, Kayser M, Introne W, Suwannarat P, Bernardini I, Fischer R, O’Brien K, Kleta R, Huizing M, Gahl WA. Mutation spectrum of homogentisic acid oxidase (HGD) in alkaptonuria. Hum Mutat 2009; 30:1611 - 9; http://dx.doi.org/10.1002/humu.21120; PMID: 19862842
   PubMed Web of Science ®Google Scholar
• Boedeker C.. Ueber das Alcapton; ein neuer Beitrag zur Frage: Welche Stoffe des Hams kannen Kupferreduction bewirken?. Ztschr f rat Med 1859; 7:130
   Google Scholar
• Boedeker C. Das Alkapton; ein Beitrag zur Frage:Welche Stoffe des Harns Konnen aus einer alkalischen Kupferoxydlosung Kupferoxydul reduciren?. Ann Chem Pharmacol 1861; 117:98; http://dx.doi.org/10.1002/jlac.18611170106
   Google Scholar
• Gaines JJ Jr.. The pathology of alkaptonuric ochronosis. Hum Pathol 1989; 20:40 - 6; http://dx.doi.org/10.1016/0046-8177(89)90200-1; PMID: 2643557
   PubMed Web of Science ®Google Scholar
• Helliwell TR, Gallagher JA, Ranganath L. Alkaptonuria--a review of surgical and autopsy pathology. Histopathology 2008; 53:503 - 12; PMID: 18336562
   PubMed Web of Science ®Google Scholar
• Peker E, Yonden Z, Sogut S, Peker E, Yonden Z, Sogut S. From darkening of urine is the early sign of alkaptonuria. Indian J Dermatol Ve 2008; 74:705
   Google Scholar
• Bradley DM. Screening for inherited metabolic disease in Wales using urine-impregnated filter paper. Arch Dis Child 1975; 50:264 - 8; http://dx.doi.org/10.1136/adc.50.4.264; PMID: 1147666
   PubMed Web of Science ®Google Scholar
• Deutsch JC, Santhosh-Kumar CR, Deutsch J, Santhoshkumar C. Quantitation of homogentisic acid in normal human plasma. J Chromatogr B Biomed Appl 1996; 677:147 - 51; http://dx.doi.org/10.1016/0378-4347(95)00442-4; PMID: 8925087
   PubMed Web of Science ®Google Scholar
• Klippel JH, Dieppe PA. Rheumatology - Volume Two. London, UK: Mosby, 1998.
   Google Scholar
• Fernández-Cañón JM, Granadino B, Beltrán-Valero de Bernabé D, Renedo M, Fernández-Ruiz E, Peñalva MA, Rodríguez de Córdoba S. The molecular basis of alkaptonuria. Nat Genet 1996; 14:19 - 24; http://dx.doi.org/10.1038/ng0996-19; PMID: 8782815
   PubMed Web of Science ®Google Scholar
• Fisher AA, Davis MW. Alkaptonuric ochronosis with aortic valve and joint replacements and femoral fracture: a case report and literature review. Clin Med Res 2004; 2:209 - 15; http://dx.doi.org/10.3121/cmr.2.4.209; PMID: 15931360
   PubMedGoogle Scholar
• O’Brien WM, La Du BN, Bunim JJ. Biochemical, pathologic and clinical aspects of alkaptonuria, ochronosis and ochronotic arthropathy. Am J Med 1963; 34:813 - 38; http://dx.doi.org/10.1016/0002-9343(63)90089-5
   Web of Science ®Google Scholar
• Manoj Kumar RV, Rajasekaran S. Spontaneous tendon ruptures in alkaptonuria. J Bone Joint Surg Br 2003; 85:883 - 6; PMID: 12931812
   PubMedGoogle Scholar
• Introne WJ, Phornphutkul C, Bernardini I, McLaughlin K, Fitzpatrick D, Gahl WA. Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation. Mol Genet Metab 2002; 77:136 - 42; http://dx.doi.org/10.1016/S1096-7192(02)00121-X; PMID: 12359141
   PubMed Web of Science ®Google Scholar
• Krízek V. Urolithiasis and prostatolithiasis in alcaptonuria with ochronosis. Int Urol Nephrol 1971; 3:245 - 50; http://dx.doi.org/10.1007/BF02081762; PMID: 5154571
   PubMedGoogle Scholar
• Gaines JJ Jr., Tom GD, Khankhanian N. An ultrastructural and light microscopic study of the synovium in ochronotic arthropathy. Hum Pathol 1987; 18:1160 - 4; http://dx.doi.org/10.1016/S0046-8177(87)80385-4; PMID: 3679190
   PubMed Web of Science ®Google Scholar
• Reginato AJ, Schumacher HR, Martinez VA. Ochronotic arthropathy with calcium pyrophosphate crystal deposition. A light and electron microscopic study. Arthritis Rheum 1973; 16:705 - 14; http://dx.doi.org/10.1002/art.1780160602; PMID: 4757869
   PubMed Web of Science ®Google Scholar
• McClure J, Smith PS, Gramp AA. Calcium pyrophosphate dihydrate (CPPD) deposition in ochronotic arthropathy. J Clin Pathol 1983; 36:894 - 902; http://dx.doi.org/10.1136/jcp.36.8.894; PMID: 6308064
   PubMed Web of Science ®Google Scholar
• Milch RA. Biochemical studies on the pathogenesis of collagen tissue changes in alcaptonuria. Clin Orthop 1962; 24:213 - 29; PMID: 14473824
   PubMedGoogle Scholar
• Perry MB, Suwannarat P, Furst GP, Gahl WA, Gerber LH. Musculoskeletal findings and disability in alkaptonuria. J Rheumatol 2006; 33:2280 - 5; PMID: 16981292
   PubMed Web of Science ®Google Scholar
• Stenn FF, Milgram JW, Lee SL, Weigand RJ, Veis A. Biochemical identification of homogentisic acid pigment in an ochronotic egyptian mummy. Science 1977; 197:566 - 8; http://dx.doi.org/10.1126/science.327549; PMID: 327549
   PubMed Web of Science ®Google Scholar
• Virchow R. Ein Fall von allgemeiner Ochronose der Knorpel und knorpelahnlichen Theile. Arch Path Anat 1866; 37:212 - 9
   Google Scholar
• Wolkow M, Baumann E. Ueber das Wesen der Alkaptonurie. Z Phys Chem 1891; 15:228 - 85
   Google Scholar
• Scriver CR. Garrod’s Croonian Lectures (1908) and the charter ‘Inborn Errors of Metabolism’: albinism, alkaptonuria, cystinuria, and pentosuria at age 100 in 2008. J Inherit Metab Dis 2008; 31:580 - 98; http://dx.doi.org/10.1007/s10545-008-0984-9; PMID: 18850300
   PubMed Web of Science ®Google Scholar
• La Du BN, Zannoni VG, Laster L, Seegmiller JE. The nature of the defect in tyrosine metabolism in alcaptonuria. J Biol Chem 1958; 230:251 - 60; PMID: 13502394
   PubMed Web of Science ®Google Scholar
• Pollak MR, Chou YH, Cerda JJ, Steinmann B, La Du BN, Seidman JG, Seidman CE. Homozygosity mapping of the gene for alkaptonuria to chromosome 3q2. Nat Genet 1993; 5:201 - 4; http://dx.doi.org/10.1038/ng1093-201; PMID: 8252048
   PubMed Web of Science ®Google Scholar
• Sealock RR, Gladstone M, Steele JM. Administration of ascorbic acid to an alkaptonuric patient. Proc Soc Exp Biol Med 1940; 44:580 - 3; http://dx.doi.org/10.3181/00379727-44-11534
   Google Scholar
• Lorenzini S, Mannoni A, Selvi E. Alkaptonuria. N Engl J Med 2003; 348:1408 - , author reply 1408; http://dx.doi.org/10.1056/NEJM200304033481421; PMID: 12672874
   PubMed Web of Science ®Google Scholar
• Forslind K, Wollheim FA, Akesson B, Rydholm U. Alkaptonuria and ochronosis in three siblings. Ascorbic acid treatment monitored by urinary HGA excretion. Clin Exp Rheumatol 1988; 6:289 - 92; PMID: 3180550
   PubMed Web of Science ®Google Scholar
• Wolff JA, Barshop B, Nyhan WL, Leslie J, Seegmiller JE, Gruber H, Garst M, Winter S, Michals K, Matalon R. Effects of ascorbic acid in alkaptonuria: alterations in benzoquinone acetic acid and an ontogenic effect in infancy. Pediatr Res 1989; 26:140 - 4; http://dx.doi.org/10.1203/00006450-198908000-00015; PMID: 2771520
   PubMed Web of Science ®Google Scholar
• de Haas V, Carbasius Weber EC, de Klerk JB, Bakker HD, Smit GP, Huijbers WA, Duran M, Poll-The BT. The success of dietary protein restriction in alkaptonuria patients is age-dependent. J Inherit Metab Dis 1998; 21:791 - 8; http://dx.doi.org/10.1023/A:1005410416482; PMID: 9870204
   PubMed Web of Science ®Google Scholar
• Ranganath LR, Jarvis JC, Gallagher JA. Recent advances in management of alkaptonuria (invited review; best practice article). J Clin Pathol 2013; 66:367 - 73; http://dx.doi.org/10.1136/jclinpath-2012-200877; PMID: 23486607
   PubMed Web of Science ®Google Scholar
• Kobak AC, Oder G, Kobak S, Argin M, Inal V. Ochronotic arthropathy: disappearance of alkaptonuria after liver transplantation for hepatitis B-related cirrhosis. J Clin Rheumatol 2005; 11:323 - 5; http://dx.doi.org/10.1097/01.rhu.0000191157.25894.55; PMID: 16371803
   PubMed Web of Science ®Google Scholar
• Alkaptonuria Society [Internet]. Cambridge (UK): Alkaptonuria Society Ltd; c2012 [cited 15 May 2013]. Available from: http://www.akusociety.org/index.html
   Google Scholar
• Introne WJPM, Perry MB, Troendle J, Tsilou E, Kayser MA, Suwannarat P, O’Brien KE, Bryant J, Sachdev V, Reynolds JC, et al. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab 2011; 103:307 - 14; http://dx.doi.org/10.1016/j.ymgme.2011.04.016; PMID: 21620748
   PubMed Web of Science ®Google Scholar
• Preston AJ, Keenan CM, Sutherland H, Wilson PJ, Wlodarski B, Taylor AM, Williams DP, Ranganath LR, Gallagher JA, Jarvis JC. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone. Ann Rheum Dis 2014; 73:284 - 9; http://dx.doi.org/10.1136/annrheumdis-2012-202878; PMID: 23511227
   PubMed Web of Science ®Google Scholar
• Medscape Reference Nitisinone (Rx) - Orfadin; adverse effects [Internet]. New York (NY): Medscape, LLC; c2014 [cited 15 May 2013]. Available from: http://reference.medscape.com/drug/orfadin-nitisinone-342859#4
   Google Scholar
• Ellaway CJ, Holme E, Standing S, Preece MA, Green A, Ploechl E, Ugarte M, Trefz FK, Leonard JV. Outcome of tyrosinaemia type III. J Inherit Metab Dis 2001; 24:824 - 32; http://dx.doi.org/10.1023/A:1013936107064; PMID: 11916315
   PubMed Web of Science ®Google Scholar
• Taylor AM. An investigation of the pathogenesis of ochronosis in Alkaptonuria (AKU) [dissertation]. Liverpool: University of Liverpool, 2011.
   Google Scholar
• Johnson EH, Miller RL. Alkaptonuria in a cynomolgus monkey (Macaca fascicularis). J Med Primatol 1993; 22:428 - 30; PMID: 8169945
   PubMed Web of Science ®Google Scholar
• Watkins SP, Benley H, Shulman NR. 2nd conference on experimental medicine and surgery in primates, New York NY. September 1969. Medical primatology 1970.: Basel: Karger.
   Google Scholar
• Keeling ME, McClure HM, Kibler RF. Alkaptonuria in an orangutan (Pongo pygmaeus). Am J Phys Anthropol 1973; 38:435 - 8; http://dx.doi.org/10.1002/ajpa.1330380245; PMID: 4689767
   PubMed Web of Science ®Google Scholar
• Lonsdale D. Why I left orthodox medicine: Healing for the 21st century. Charlottesville, VA: Hampton Roads Publishing Company, 1994.
   Google Scholar
• Lewis JH. Alcaptonuria in a rabbit. J Biol Chem 1926; 70:659
   Google Scholar
• Moran TJ, Yunis EJ. Studies on ochronosis. 2. Effects of injection of homogentisic acid and ochronotic pigment in experimental animals. Am J Pathol 1962; 40:359 - 69; PMID: 14475795
   PubMed Web of Science ®Google Scholar
• Blivaiss BB, Rosenberg EF, Kutuzov H, Stoner R. Experimental ochronosis. Induction in rats by long-term feeding with L-tyrosine. Arch Pathol 1966; 82:45 - 53; PMID: 5938449
   PubMedGoogle Scholar
• Montagutelli X, Lalouette A, Coudé M, Kamoun P, Forest M, Guénet JL. aku, a mutation of the mouse homologous to human alkaptonuria, maps to chromosome 16. Genomics 1994; 19:9 - 11; http://dx.doi.org/10.1006/geno.1994.1004; PMID: 8188247
   PubMed Web of Science ®Google Scholar
• Manning K, Fernández-Cañón JM, Montagutelli X, Grompe M. Identification of the mutation in the alkaptonuria mouse model. Mutations in brief no. 216. Online. Hum Mutat 1999; 13:171; http://dx.doi.org/10.1002/(SICI)1098-1004(1999)13:2<171::AID-HUMU15>3.0.CO;2-W; PMID: 10094559
   PubMedGoogle Scholar
• Suzuki Y, Oda K, Yoshikawa Y, Maeda Y, Suzuki T. A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria. J Hum Genet 1999; 44:79 - 84; http://dx.doi.org/10.1007/s100380050114; PMID: 10083729
   PubMed Web of Science ®Google Scholar
• Taylor AM, Preston AJ, Paulk NK, Sutherland H, Keenan CM, Wilson PJ, Wlodarski B, Grompe M, Ranganath LR, Gallagher JA, et al. Ochronosis in a murine model of alkaptonuria is synonymous to that in the human condition. Osteoarthritis Cartilage 2012; 20:880 - 6; http://dx.doi.org/10.1016/j.joca.2012.04.013; PMID: 22542924
   PubMed Web of Science ®Google Scholar
• Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J, Rodan GA, Duong T. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004; 50:1193 - 206; http://dx.doi.org/10.1002/art.20124; PMID: 15077302
   PubMed Web of Science ®Google Scholar
• Castañeda S, Roman-Blas JA, Largo R, Herrero-Beaumont G. Subchondral bone as a key target for osteoarthritis treatment. Biochem Pharmacol 2012; 83:315 - 23; http://dx.doi.org/10.1016/j.bcp.2011.09.018; PMID: 21964345
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P, Altman RD, Christiansen C. Should subchondral bone turnover be targeted when treating osteoarthritis?. Osteoarthritis Cartilage 2008; 16:638 - 46; http://dx.doi.org/10.1016/j.joca.2008.01.014; PMID: 18362080
   PubMed Web of Science ®Google Scholar
• Bálint G, Szebenyi B. Hereditary disorders mimicking and/or causing premature osteoarthritis. Baillieres Best Pract Res Clin Rheumatol 2000; 14:219 - 50; http://dx.doi.org/10.1053/berh.2000.0063; PMID: 10925743
   PubMed Web of Science ®Google Scholar
• Lagier R. Ochronotic arthropathy, an approach to osteoarthritis bone remodelling. Rheumatol Int 2006; 26:561 - 4; http://dx.doi.org/10.1007/s00296-005-0087-y; PMID: 16435121
   PubMed Web of Science ®Google Scholar
• van Lierop AH, Hamdy NAT, van Bezooijen RL, Lowik CW, Papapoulos SE. The role of sclerostin in the pathophysiology of sclerosing bone dysplasias. Clinical Reviews in Bone and Mineral Metabolism 2012; 10:108; http://dx.doi.org/10.1007/s12018-011-9123-5
   Google Scholar
• Moester MJC, Papapoulos SE, Löwik CW, van Bezooijen RL. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 2010; 87:99 - 107; http://dx.doi.org/10.1007/s00223-010-9372-1; PMID: 20473488
   PubMed Web of Science ®Google Scholar